Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Safety and Efficacy of Avacopan in ANCA-Associated Vasculitis
NCT06072482Phase 4Recruiting
- Sponsor
- Amgen
- Start
- Feb 2024
- Primary completion
- Dec 2036
- Modality
- Small Molecules
- Countries
- 7
01
Overview
A Phase 4 trial of avacopan in anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV), sponsored by Amgen. Started Feb 2024; status: recruiting.
02
Drugs
avacopan
03
Conditions
anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV)
Beyond the preview
Go deeper on NCT06072482.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06072482.